Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Surawase Rajendra, K.
- Solubilty Enhancement of Naproxen Sodium using Different Carriers by Solid Dispersion
Abstract Views :153 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, Loknete Dr. J D Pawar College of Pharmacy, Manur, Tal. Kalwan – 423501, Dist. Nashik, (MH), IN
1 Department of Pharmaceutics, Loknete Dr. J D Pawar College of Pharmacy, Manur, Tal. Kalwan – 423501, Dist. Nashik, (MH), IN
Source
Asian Journal of Pharmacy and Technology, Vol 12, No 1 (2022), Pagination: 1-5Abstract
In the existing study an attempt has been made to increase the in vitro dissolution rate of poorly water-soluble drug naproxen, by utilizing novel solid dispersion methods are one of the most auspicious methods to enhance the oral bioavailability of poorly water soluble drug. naproxen sodium formulations were planned out by using melting method or fusion method, and using carrier like PVP-K30 and PEG4000. the formulation were planned out with the above-mentioned carriers in three different drug-carrier (w/w) ratios of 1:1, 1:2 and 1:3. the prepared solid dispersion was subjected for percentage practical yield, drug content, and FTIR studies. absence of significant drug-carrier interaction was confirmed by FTIR data. in-vitro release profiles of all solid dispersions (SD1 to SD6) were analogously evaluated and also studied against pure naproxen sodium. solid dispersion of formulation (SD6) naproxen sodium and PVP-K30 combination planned out in (1:3) ratio showed excellent solubility and the dissolution rate was found to be 98.97% drug release at 24 min was chosen as the absolute best formulation in this study. solubility of naproxen sodium was increased as the concentration of carriers increased.Keywords
Naproxen Sodium, Solid Dispersion, Solvent Evaporation, PVP-K30, PEG4000 Solubility
References
- Mayersohn M., Gibaldi M. et al New method of solid state dispersion for increasing dissolution rates. J Pharm Sci. 1966; 55: 1323-1342.
- Taylor L.S., Zografi G. et al Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997 14(12): 1691-1698.
- Chirag A. Patel, Priyal R. Patel, Dhrubo Jyoti Sen, Jayvadan K. Patel. et al Enhancement of Solubility of Poorly Water-Soluble Drug (Allopurinol) Through Solid Dispersion. Research J. Pharma. Dosage Forms and Tech. 2010; 2(2):156-163.
- Constantinides P.P. et al Lipid micro-emulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects, Pharm. Res. 1995; 12; 1561 1572.
- Jung J., Perrut M. et al Particle design using supercritical fluids: literature and patent survey, J. Supercrit. Fluids 2001; 20; 179 219.
- Kakumanu V. K., Bansal A. K. et al Supercritical Fluid Technology in Pharmaceutical Research. Businessbriefing: Labtech, 2004; 70-72.
- Kaushal, A.M, Guptam P., and Bansal, AK. et al Amorphous drug delivery systems: molecular aspects, design, and performance. Crit. Rev. There. Drug Carrier Syst., 2004; 21(3): 133-193.
- Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000; 50(1): 47-60.
- Majerik V., Horvath G., Charbit G., Badens E., Szokonya L., Bosc N., Teillaud E. et al Novel particle engineering techniques in drug delivery: review of formulations using supercritical fluids and liquefied gases, Hun. J. Ind. Chem. 2004; 32; 41 56
- Mayersohn M., Gibaldi M. New method of solid state dispersion for increasing dissolution rates. J Pharm Sci. 1966; 55: 1323-1342.
- Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. et al Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm. 2008; 355(1-2): 141-149. doi:10.1016/j.ijpharm.2007.12.017.
- Murali Mohan Babu GV, Prasad ChD, Ramana Murthy KV. et al Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine. Int J Pharm. 2002; 234(1-2): 1-17. doi:10.1016/S0378-5173(01)00925-5.
- Spencer CM, Wilde MI. et al Diacerein. Drugs. 1997; 53(1): 98-106.
- Fidelix T, Macedo CR, Maxwell LJ. et al Diacerein for osteoarthritis. Cochrane Database. 2006.
- Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. et al Evaluation of the structure modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of hip. Arthritis Rheum. 2001; 44(11): 2539-2547.
- Smith GN, Myers SL, Brandt KD, Mickler EA, Albrecht ME. et al Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate deficiency model of osteoarthritis. Arthritis Rheum. 1999; 42(3): 545-554. doi: 10.1002/1529-0131(199904)42:3<545:AID-ANR20>3.0.CO;2-4.
- Felisaz N, Boumediene K, Ghayor C, Herrouin JF, Galerra P. et al Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage. 1999; 7(3): 255-264. doi: 10.1053/joca.1998.0199.
- Mogal Prasad S, Dode Raj H, Surawase Rajendra K. et al Solid dispersion: A magnificent app. to improve sol. of poorly soluble drugs. Ejbps,2021;8(5): 171-176.
- Gao D, Wu JS, Lu WS, Chen S, Kuo PC, Chen CM. et al. Pharmaceutical composition containing diacerein. US 2010/0104651A1. TWi Biotechnology Inc. 2010; 4: 29.
- Zografil G, Newman A. et al Introduction to amorphous solid dispersions. In: Gad SC (ed). Pharmaceutical Amorphous Solid Dispersions. 1st edition, John Wiley & Sons, Inc. 2015. doi: 10.1002/9780470571224.pse522